Drugs / PF-00337210
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01105533 | May 2006 → Oct 2010 | neoplasm | Pfizer | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-00337210 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01105533 ↗ |
| Known as | Pf-337210 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1738697 ↗ |
| Action | Inhibit | “This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor.” NCT01105533 ↗1“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL1738697 ↗ |
| Modality | Small molecule | — CHEMBL1738697 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL1738697 ↗ |